ImmuCell Short Interest Surges 44% in February

Biotech firm sees significant increase in shares sold short amid market volatility.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

ImmuCell Corporation (NASDAQ:ICCC), a biotechnology company focused on animal health products, saw a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 18,071 shares, a growth of 44.1% from the January 29th total of 12,544 shares. Based on the company's average daily trading volume of 17,639 shares, the short-interest ratio is currently 1.0 days, meaning it would take one trading day for short sellers to cover their positions.

Why it matters

The rise in short interest for ImmuCell could indicate increased bearish sentiment among investors, potentially driven by market volatility or concerns about the company's performance. Short selling activity is often seen as a barometer of investor sentiment and can provide insights into the market's perception of a company's prospects.

The details

ImmuCell is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays for animal health in the dairy and beef cattle industries. The company's flagship product is CalfGuard, a natural colostrum supplement formulated to promote passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.

  • As of February 13th, 2026, there was short interest totaling 18,071 shares.
  • This represents a 44.1% increase from the January 29th, 2026 total of 12,544 shares.

The players

ImmuCell Corporation

A biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays for animal health in the dairy and beef cattle industries.

Geode Capital Management LLC

An institutional investor that owns 71,852 shares of ImmuCell, representing a 4.2% increase in its position during the second quarter.

Mesirow Financial Investment Management Inc.

An institutional investor that owns 36,481 shares of ImmuCell, representing a 199.6% increase in its position during the fourth quarter.

Steadtrust LLC

An institutional investor that owns 56,770 shares of ImmuCell, representing a 79.1% increase in its position during the fourth quarter.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in short interest for ImmuCell Corporation highlights the volatility and uncertainty surrounding the biotech sector, as investors may be taking bearish positions on the company's prospects. However, the upgrade from Weiss Ratings suggests that the company's fundamentals may be improving, and investors should closely monitor the company's performance and market sentiment in the coming months.